Drugs / AZD5335
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07402915 | Jan 2026 → Oct 2027 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05797168 | Jun 2023 → Jan 2028 expected | endometrial cancer, lung adenocarcinoma, ovarian cancer, squamous cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07218809 | Dec 2025 → Nov 2028 expected | ovarian epithelial tumor | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5335 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07402915 ↗ |
| Known as | Torvutatug samrotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797168 ↗ |
| Action | Inhibit | “the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335” NCT07402915 ↗ |
| Modality | Other / unclassified | “IV Antibody-drug conjugate” NCT05797168 ↗ |
| Route | Intravenous | “IV Antibody-drug conjugate” NCT05797168 ↗ |